HC Wainwright & Co. Reiterates Buy on Harpoon Therapeutics, Maintains $4.5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Harpoon Therapeutics (NASDAQ:HARP) and maintained a price target of $4.5.
August 10, 2023 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harpoon Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $4.5.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Harpoon Therapeutics. The maintained price target of $4.5 also indicates the firm's confidence in the stock's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100